These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 25985864)

  • 1. Liraglutide: a review of its use in the management of obesity.
    Scott LJ
    Drugs; 2015 May; 75(8):899-910. PubMed ID: 25985864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naltrexone ER/Bupropion ER: A Review in Obesity Management.
    Greig SL; Keating GM
    Drugs; 2015 Jul; 75(11):1269-80. PubMed ID: 26105116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide: A New Option for the Treatment of Obesity.
    Nuffer WA; Trujillo JM
    Pharmacotherapy; 2015 Oct; 35(10):926-34. PubMed ID: 26497479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials.
    Ard J; Cannon A; Lewis CE; Lofton H; Vang Skjøth T; Stevenin B; Pi-Sunyer X
    Diabetes Obes Metab; 2016 Apr; 18(4):430-5. PubMed ID: 26744025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
    le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS; Pi-Sunyer X;
    Lancet; 2017 Apr; 389(10077):1399-1409. PubMed ID: 28237263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study.
    Gorgojo-Martínez JJ; Basagoiti-Carreño B; Sanz-Velasco A; Serrano-Moreno C; Almodóvar-Ruiz F
    Int J Clin Pract; 2019 Nov; 73(11):e13399. PubMed ID: 31397946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ▾ Liraglutide for weight management.
    Drug Ther Bull; 2017 Jul; 55(7):78-81. PubMed ID: 28701318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS.
    O'Neil PM; Garvey WT; Gonzalez-Campoy JM; Mora P; Ortiz RV; Guerrero G; Claudius B; Pi-Sunyer X;
    Endocr Pract; 2016 Nov; 22(11):1277-1287. PubMed ID: 27482610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
    Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
    JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide in Obese or Overweight Individuals With Stable Bipolar Disorder.
    McElroy SL; Guerdjikova AI; Blom TJ; Mori N; Romo-Nava F
    J Clin Psychopharmacol; 2024 Mar-Apr 01; 44(2):89-95. PubMed ID: 38227621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient initiation and maintenance of GLP-1 RAs for treatment of obesity: a narrative review and practical considerations for primary care providers.
    Fitch A; Ingersoll AB
    Postgrad Med; 2021 Apr; 133(3):310-319. PubMed ID: 33151791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacotherapy for obesity].
    Bruun JM
    Ugeskr Laeger; 2016 Oct; 178(44):. PubMed ID: 27808050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
    Tronieri JS; Wadden TA; Walsh OA; Berkowitz RI; Alamuddin N; Gruber K; Leonard S; Chao AM
    Metabolism; 2019 Jul; 96():83-91. PubMed ID: 30902750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Current Role of Liraglutide in the Pharmacotherapy of Obesity.
    Christou GA; Katsiki N; Kiortsis DN
    Curr Vasc Pharmacol; 2016; 14(2):201-7. PubMed ID: 26074046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
    Astrup A; Rössner S; Van Gaal L; Rissanen A; Niskanen L; Al Hakim M; Madsen J; Rasmussen MF; Lean ME;
    Lancet; 2009 Nov; 374(9701):1606-16. PubMed ID: 19853906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial.
    Whicher CA; Price HC; Phiri P; Rathod S; Barnard-Kelly K; Reidy C; Thorne K; Asher C; Peveler R; McCarthy J; Holt RIG
    Trials; 2019 Nov; 20(1):633. PubMed ID: 31747930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide: A Glucagon-Like Peptide-1 Agonist for Chronic Weight Management.
    Manigault KR; Thurston MM
    Consult Pharm; 2016 Dec; 31(12):685-697. PubMed ID: 28074747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and Emerging Pharmacotherapies for Weight Management in Prediabetes and Diabetes.
    Lau DC; Teoh H
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S134-41. PubMed ID: 26654857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological Treatment for Obesity in Adults: An Umbrella Review.
    Khalil H; Ellwood L; Lord H; Fernandez R
    Ann Pharmacother; 2020 Jul; 54(7):691-705. PubMed ID: 31958967
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.